Pfizer is not happy with a recent PLoS Medicine paper that details the extent to which the company’s subsidiary Wyeth has used ghostwriting to promote its hormone replacement therapies, says Pharmalot’s Ed Silverman.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.